Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Hancock Whitney Q1 EPS $1.40 Beats $1.32 Estimate

Hancock Whitney (NASDAQ:HWC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.32 by 6.06 percent. This is a 15.7 percent increase over earnings of $1.21 per share from the
byBenzinga Newsdesk
April 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Hancock Whitney (NASDAQ:HWC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.32 by 6.06 percent. This is a 15.7 percent increase over earnings of $1.21 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aileron Therapeutics Announced Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

By Charles Gross
June 29, 6:32 AM
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated NSCLC undergoing treatment with first-line carbopla

ALRN